{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:43Z","timestamp":1760028463886,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ahj.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T16:32:48Z","timestamp":1551457968000},"page":"13-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial"],"prefix":"10.1016","volume":"212","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mick","family":"Ozkor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Vardas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Miede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurrien M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ahj.2019.02.006_bb0005","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ahj.2019.02.006_bb0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2013.11.030","article-title":"Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry","volume":"170","author":"Ruff","year":"2014","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2019.02.006_bb0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1160\/TH10-05-0332","article-title":"Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes","volume":"104","author":"Depta","year":"2010","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ahj.2019.02.006_bb0020","first-page":"93","article-title":"Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents","volume":"6","author":"Steg","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ahj.2019.02.006_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective-2018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2019.02.006_bb0030","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2009.06.027","article-title":"Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes","volume":"104","author":"Depta","year":"2009","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ahj.2019.02.006_bb0035","first-page":"204","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2019.02.006_bb0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ahj.2019.02.006_bb0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/clc.22750","article-title":"Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events","volume":"40","author":"Lemesle","year":"2017","journal-title":"Clin Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2019.02.006_bb0050","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.amjmed.2017.03.057","article-title":"Safety and efficacy of dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention","volume":"130","author":"Agarwal","year":"2017","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ahj.2019.02.006_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ehjcvp\/pvx033","article-title":"Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"4","author":"Batra","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9872","key":"10.1016\/j.ahj.2019.02.006_bb0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ahj.2019.02.006_bb0065","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.ahj.2019.02.006_bb0070","doi-asserted-by":"crossref","first-page":"1726-35a","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2019.02.006_bb0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.ahj.2019.02.006_bb0080","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ahj.2019.02.006_bb0085","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"9921","key":"10.1016\/j.ahj.2019.02.006_bb0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ahj.2019.02.006_bb0095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2019.02.006_bb0100","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2019.02.006_bb0105","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2019.02.006_bb0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ahj.2019.02.006_bb0115","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2019.02.006_bb0120","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2019.02.006_bb0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"Cannon","year":"2016","journal-title":"Clin Cardiol"},{"author":"Boehringer Ingelheim","key":"10.1016\/j.ahj.2019.02.006_bb0130"},{"issue":"5","key":"10.1016\/j.ahj.2019.02.006_bb0135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ahj.2019.02.006_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ahj.2019.02.006_bb0145","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: Comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ahj.2019.02.006_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2019.02.006_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2019.02.006_bb0160","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2014.01.007","article-title":"CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"133","author":"Puurunen","year":"2014","journal-title":"Thromb Res"},{"author":"European Medicines Agency","key":"10.1016\/j.ahj.2019.02.006_bb0165"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:01:45Z","timestamp":1757570505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":33,"alternative-id":["S0002870319300407"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.02.006","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}